Pri-Med Washington, D.C | March 2026

Wednesday−Thursday, March 18–19|Washington, DC

Pri-Med Washington, D.C. | Medical Conference

Andrew E. Budson, MD
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Stephen N. Henry, DO, MS
Pamela Kushner, MD, FAAFP
Dr. Pamela Kushner

Learn More

Thursday, March 19 8:30–9:30am

Common Cases in Primary Care: From Intake to Action

Peter Lin, MD, CCFP
Joynita R. Nicholson, DO, DABOM, MFOMA
Vani Potluri, MD
Jeffrey Rado, MD, MPH, FAPA

Learn More

Wednesday, March 18 3:45–4:30pm

Beyond SSRIs: Treating Complicated Depression

Vicky Ren, MD, FAAD
Athica Vatanapradith, MD, DABOM
Charles Vega, MD, FAAFP

Earn CME/CE credits in Washington, D.C.

Register Now

Financial Disclosures

Andrew E. Budson, MD
Advisor: AbbVie; Speaker: Eli Lilly; Researcher: Vox Neuro, Eisai
Amy Clouse, MD, FAAFP
Stock Holder (publicly traded company): Eli Lilly and Novo Nordisk Inc.
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Consultant: OptumRx
Stephen N. Henry, DO, MS
No relevant financial relationships disclosed.
Pamela Kushner, MD, FAAFP
Advisor: GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novo Nordisk, Lilly, Bausch/SALIX, Haleon, Verdiva, Abbott, Corcept, and Bayer; Speaker: GlaxoSmithKline, Boehringer Ingelheim, Phathom, AstraZeneca, Novo Nordisk, Lilly, Janssen, Haleon, Corcept, and Lilly
Peter Lin, MD, CCFP
Speaker: Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eisai, Eli Lilly, GlaxoSmithKline, Medtronic, Merck, Moderna, Novo Nordisk, Pfizer, Sanofi
Joynita R. Nicholson, DO, DABOM, MFOMA
Advisor: Corcept Therapeutics
Vani Potluri, MD
No relevant financial relationships disclosed.
Jeffrey Rado, MD, MPH, FAPA
Speaker: Alkermes; Researcher: Cerevel, Neurorelief, NRX Pharmaceuticals; Consultant: Paraxel
Vicky Ren, MD, FAAD
No relevant financial relationships disclosed.
Athica Vatanapradith, MD, DABOM
Speaker: Inspire
Charles Vega, MD, FAAFP
Consultant: GlaxoSmithKline, Boehringer Ingelheim, Exact Sciences

Other Disclosures

All other non-faculty contributors involved in the moderating, planning, development, editing and review of the content have disclosed no relevant financial relationships.